Therefore, we hypothesized that a monovalent antibody, that could bind to the GluN1-NTD and block the binding of bivalent pathogenic autoantibodies and crosslinking of NMDARs without impacting NMDAR function, could have therapeutic potential in the treatment of anti-NMDAR encephalitis (Fig. 1a). Here, GRIN1 is linked to encephalitis.